Friday, April 26, 2024

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

RSV Vaccines for Senior Adults Linked to Guillain-Barré Syndrome

holding vial of RSV vaccine

On Feb. 29, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) presented a preliminary analysis that showed that 23 adults over the age of 65 who received a respiratory syncytial virus (RSV) vaccine developed Guillain-Barré syndrome (GBS).1 When a person develops GBS, including after an infection or […]

Influenza Vaccines Only 42 Percent Effective in Adults This Year

doubting man

The influenza vaccines currently being administered in the United States are estimated by the U.S. Centers for Disease Control and Prevention (CDC) to be 42 percent effective in adults. This is an interim estimate for the 2023-2024 “flu season” published in the agency’s Morbidity and Mortality Weekly Report (MMWR) on Feb. 29, 2024.1 2 3 […]

Novel mRNA Lyme Shots Could Be Released in 2025

test tube and tick

Two novel messenger RNA (mRNA) shots for Lyme disease currently in late-stage clinical trials could hit the market as early as 2025, Moderna announced earlier this year. Also in the race to develop the first-ever mRNA product to prevent Lyme disease are Pfizer and Austria-based Valneva, which entered into a collaborative agreement in April 2020 […]

CDC Says All Children Traveling Abroad Need Extra MMR Shot to Prevent Measles in U.S.

children at airport

After 16 cases of measles were reported in the U.S. linked to international travel, the U.S. Centers for Disease Control and Prevention (CDC) issued a health alert on June 21, 2023, recommending that all eligible infants aged six months or older get an extra measles vaccine before traveling abroad this summer. Despite being licensed by […]

Twelve Infants Die During Clinical Trials for FDA-Endorsed RSV Drug

On June 8, 2023, the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously (21-0) in favor of AstraZeneca and Sanofi’s new nirsevimab (Beyfortus) monoclonal antibody drug believed to provide protection for infants from respiratory syncytial virus (RSV) disease and other lower respiratory tract infections during their first year of life.1 […]

Search in Site

To search in site, type your keyword and hit enter

Search